8-K filing — 20/20 Biolabs, Inc. (AIDX)
Filed: 2026-08-17 AccNo: 0001213900-26-090746 Size: 327 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
BioLabs Announces Standstill Agreement With Streeterville Capital Regarding Outstanding Series E Convertible Preferred Stock, Effective July 16
Under the terms of the Agreement, during the 120-day period beginning on the date of the Agreement, Streeterville has agreed not to convert any shares of Series E Preferred Stock into shares of the Company’s common
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 23, 2026, 12:41 PM
- Checked
- Jul 23, 2026, 12:41 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
20/20 Biolabs Q2 EPS $(0.26) Misses $(0.06) Estimate, Sales $730.571K Miss $891.000K Estimate
20/20 Biolabs (NASDAQ:AIDX) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.06) by 333.33 percent. This is a 52.94 percent decrease over losses of $(0.17) per share from
Read original at benzinga20/20 BioLabs Mulls Merger, Acquisition, Licensing, JV, Commercial Collaborations Across East Asia Under Its Roll-Up Strategy
20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20 Biolabs" or the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic
Read original at benzinga